SG11201703307WA - Therapy for inhibition of single-stranded rna virus replication - Google Patents
Therapy for inhibition of single-stranded rna virus replicationInfo
- Publication number
- SG11201703307WA SG11201703307WA SG11201703307WA SG11201703307WA SG11201703307WA SG 11201703307W A SG11201703307W A SG 11201703307WA SG 11201703307W A SG11201703307W A SG 11201703307WA SG 11201703307W A SG11201703307W A SG 11201703307WA SG 11201703307W A SG11201703307W A SG 11201703307WA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibition
- therapy
- stranded rna
- rna virus
- virus replication
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068465P | 2014-10-24 | 2014-10-24 | |
| US201462068487P | 2014-10-24 | 2014-10-24 | |
| US201462068469P | 2014-10-24 | 2014-10-24 | |
| US201462068477P | 2014-10-24 | 2014-10-24 | |
| US201462068492P | 2014-10-24 | 2014-10-24 | |
| US201562188030P | 2015-07-02 | 2015-07-02 | |
| PCT/IB2015/002173 WO2016063134A1 (fr) | 2014-10-24 | 2015-10-23 | Thérapie pour l'inhibition de la réplication d'un virus à arn simple brin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201703307WA true SG11201703307WA (en) | 2017-05-30 |
Family
ID=55760346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201703307WA SG11201703307WA (en) | 2014-10-24 | 2015-10-23 | Therapy for inhibition of single-stranded rna virus replication |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9974800B2 (fr) |
| EP (2) | EP4134076A1 (fr) |
| JP (1) | JP6625631B2 (fr) |
| KR (1) | KR20170070234A (fr) |
| CN (2) | CN107106525B (fr) |
| AU (2) | AU2015334590B2 (fr) |
| BR (1) | BR112017008220A2 (fr) |
| CA (1) | CA2965258C (fr) |
| IL (1) | IL251847A0 (fr) |
| MX (1) | MX2017005350A (fr) |
| SG (1) | SG11201703307WA (fr) |
| WO (1) | WO2016063134A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4134076A1 (fr) * | 2014-10-24 | 2023-02-15 | Redhill Biopharma Ltd. | Thérapie pour l'inhibition de la réplication de virus rna simple brin |
| RU2727474C2 (ru) * | 2015-10-06 | 2020-07-21 | Редхилл Байофарма Лтд. | Виды комбинированной терапии для лечения рака |
| CN108853106B (zh) * | 2017-05-09 | 2021-02-02 | 中国食品药品检定研究院 | 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途 |
| US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
| DE102018217334A1 (de) | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel |
| WO2020185637A1 (fr) * | 2019-03-08 | 2020-09-17 | The Texas A&M University System | Clones infectieux du rose rosette virus et leurs utilisations |
| US20210244705A1 (en) * | 2020-02-07 | 2021-08-12 | Centre For Digestive Diseases | Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection |
| BR112022017923A2 (pt) * | 2020-03-10 | 2022-10-18 | Redhill Biopharma Ltd | Tratamento de infecção por coronavírus |
| EP3932409A1 (fr) * | 2020-06-29 | 2022-01-05 | Consejo Superior de Investigaciones Científicas (CSIC) | Composés pour le traitement et la prévention des infections virales causées par les coronavirus |
| US11298412B2 (en) | 2020-07-16 | 2022-04-12 | Harbins Ruhr Bioscience, Inc. | Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| US6335339B1 (en) * | 1998-01-13 | 2002-01-01 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
| AP2001002051A0 (en) * | 1998-07-15 | 2001-03-31 | Hassan Jomaa | Phosphorous organic compounds and their use. |
| ES2477118T3 (es) * | 2002-11-18 | 2014-07-15 | Polaris Group | Método para inhibir la replicaci�n viral in vivo |
| US7338961B2 (en) * | 2005-06-17 | 2008-03-04 | Apogee Biotechnology Corporation | Sphingosine kinase inhibitors |
| GB0803707D0 (en) | 2008-02-28 | 2008-04-09 | Cambridge Entpr Ltd | Antiviral agent |
| KR101420094B1 (ko) * | 2010-10-27 | 2014-07-17 | (주)바이오니아 | 다양한 생체시료분석을 위한 전자동실시간정량증폭장비, 다양한 생체시료분석을 위한 자동정제 및 반응준비 장치, 전자동 핵산정제 및 실시간 정량 유전자증폭 방법, 전자동 핵산정제방법, 실시간정량ｐｃｒ을 이용한 병원균의 전자동 생균수검사방법, 정량면역ｐｃｒ을 이용한 전자동 항원농도획득방법 및 타겟항원에 라벨링된 부착용 타겟핵산의 정제방법 |
| WO2012166859A2 (fr) * | 2011-06-01 | 2012-12-06 | The Curators Of The University Of Missouri | Modulation des enzymes du métabolisme de la sphingosine 1-phosphate pour le traitement d'infections par un virus à arn à brin à polarité négative |
| EP4134076A1 (fr) * | 2014-10-24 | 2023-02-15 | Redhill Biopharma Ltd. | Thérapie pour l'inhibition de la réplication de virus rna simple brin |
| RU2727474C2 (ru) * | 2015-10-06 | 2020-07-21 | Редхилл Байофарма Лтд. | Виды комбинированной терапии для лечения рака |
-
2015
- 2015-10-23 EP EP22190806.4A patent/EP4134076A1/fr active Pending
- 2015-10-23 JP JP2017521992A patent/JP6625631B2/ja not_active Expired - Fee Related
- 2015-10-23 CN CN201580071321.3A patent/CN107106525B/zh not_active Expired - Fee Related
- 2015-10-23 BR BR112017008220-9A patent/BR112017008220A2/pt not_active Application Discontinuation
- 2015-10-23 US US14/921,661 patent/US9974800B2/en active Active
- 2015-10-23 SG SG11201703307WA patent/SG11201703307WA/en unknown
- 2015-10-23 EP EP15852527.9A patent/EP3209290A4/fr not_active Withdrawn
- 2015-10-23 CN CN202110229970.9A patent/CN112999222B/zh active Active
- 2015-10-23 KR KR1020177013646A patent/KR20170070234A/ko unknown
- 2015-10-23 WO PCT/IB2015/002173 patent/WO2016063134A1/fr active Application Filing
- 2015-10-23 MX MX2017005350A patent/MX2017005350A/es unknown
- 2015-10-23 AU AU2015334590A patent/AU2015334590B2/en not_active Ceased
- 2015-10-23 CA CA2965258A patent/CA2965258C/fr active Active
-
2017
- 2017-04-23 IL IL251847A patent/IL251847A0/en unknown
-
2018
- 2018-05-02 US US15/969,526 patent/US10543222B2/en active Active
-
2019
- 2019-11-27 AU AU2019271958A patent/AU2019271958B2/en not_active Ceased
-
2020
- 2020-01-24 US US16/751,931 patent/US11090325B2/en active Active
-
2021
- 2021-08-13 US US17/401,950 patent/US11786541B2/en active Active
-
2023
- 2023-09-12 US US18/465,722 patent/US20240108643A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4134076A1 (fr) | 2023-02-15 |
| US11786541B2 (en) | 2023-10-17 |
| US10543222B2 (en) | 2020-01-28 |
| US20200155585A1 (en) | 2020-05-21 |
| EP3209290A1 (fr) | 2017-08-30 |
| JP6625631B2 (ja) | 2019-12-25 |
| BR112017008220A2 (pt) | 2018-01-09 |
| US20240108643A1 (en) | 2024-04-04 |
| US20180318328A1 (en) | 2018-11-08 |
| CN107106525B (zh) | 2021-03-19 |
| AU2019271958B2 (en) | 2020-03-05 |
| IL251847A0 (en) | 2017-06-29 |
| JP2017531673A (ja) | 2017-10-26 |
| AU2019271958A1 (en) | 2019-12-19 |
| CN107106525A (zh) | 2017-08-29 |
| WO2016063134A1 (fr) | 2016-04-28 |
| AU2015334590A1 (en) | 2017-05-18 |
| CA2965258C (fr) | 2023-09-19 |
| MX2017005350A (es) | 2017-08-15 |
| CN112999222A (zh) | 2021-06-22 |
| AU2015334590B2 (en) | 2019-08-29 |
| CN112999222B (zh) | 2024-05-28 |
| CA2965258A1 (fr) | 2016-04-28 |
| EP3209290A4 (fr) | 2018-11-14 |
| US20210369754A1 (en) | 2021-12-02 |
| US11090325B2 (en) | 2021-08-17 |
| US9974800B2 (en) | 2018-05-22 |
| KR20170070234A (ko) | 2017-06-21 |
| US20160113954A1 (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251847A0 (en) | Treatment to inhibit replication of a single-stranded RNA virus | |
| HK1225968A1 (zh) | 用於治療hbv感染的組合療法 | |
| IL253945B (en) | kdm1a inhibitors to treat the disease | |
| IL247973A0 (en) | Methods for purifying messenger RNA | |
| SG11201707663SA (en) | Lyophilization of rna | |
| PT3212233T (pt) | Terapia combinada para o tratamento de doenças | |
| SG11201701723XA (en) | Methods of treating liver disease | |
| PT3286166T (pt) | Inibidores de replicação do vírus da imunodeficiência humana | |
| GB201701673D0 (en) | Methods of well treatment | |
| HK1225617A1 (zh) | 作為流感rna複製的抑制劑的4’-二氟甲基取代的核苷衍生物 | |
| IL247364A0 (en) | c5a inhibitors for the treatment of viral pneumonia | |
| HK1251166A1 (zh) | 平滑肌肉瘤的靶向療法 | |
| ZA201700183B (en) | Acetylcholinesterase inhibitors for treatment of dermatological conditions | |
| LT3164394T (lt) | Gls1 inhibitoriai, skirti ligų gydymui | |
| IL246721B (en) | History of 5-benzylisoquinoline for the treatment of cardiovascular diseases | |
| HK1258994A1 (zh) | 用於疾病治療的方法 | |
| HK1252245A1 (zh) | 用於治療癌症的核苷酸 | |
| GB201416832D0 (en) | Methods of treatment | |
| PT3107913T (pt) | Inibidores da replicação do vírus da imunodeficiência humana | |
| SG11201703330YA (en) | Iminosugars useful for the treatment of viral diseases | |
| PT3105236T (pt) | Macrociclos de benzotiazole como inibidores da replicação do vírus da imunodeficiência humana | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201403369D0 (en) | RNA Virus induced gene expression | |
| GB201421812D0 (en) | New therapeutic uses of enzyme inhibitors | |
| GB201410529D0 (en) | New therapeutic uses of enzyme inhibitors |